The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
Open accessAbstract
Background: PD-L1 expression is the only FDA-approved biomarker for immune checkpoint inhibitors (ICIs) in patients with lung adenocarcinoma, but sensitivity is modest. Understanding the impact of molecular phenotype, clinical characteristics, and tumor features on PD-L1 expression is largely unknown and may improve prediction of response to ICI. Methods: We evaluated patients with lung adenocarcinoma in whom PD-L1 testing and targeted next-generation sequencing (MSK-IMPACT) was performed on the same tissue. Clinical and molecular features were compared across PD-L1 subgroups to examine how molecular phenotype associated with tumor PD-L1 expression. In patients treated with anti-PD-(L)1 blockade, we assessed how these interactions impacted efficacy. Results: 1586 patients with lung adenocarcinoma had paired PD-L1 testing and targeted next-generation sequencing. PD-L1 negativity was more common in primary compared to metastatic samples (p <0.001). The distribution of PD-L1 expression (lymph nodes enriched for PD-L1 high; bones predominantly PD-L1 negative) and predictiveness of PD-L1 expression on ICI response varied by organ. Mutations in KRAS, TP53, and MET significantly associated with PD-L1 high expression (each p < 0.001, q < 0.001) and EGFR and STK11 mutations associated with PD-L1 negativity (p <0.001, q = 0.01; p = 0.001, q < 0.001, respectively). WNT pathway alterations also associated with PD-L1 negativity (p = 0.005). EGFR and STK11 mutants abrogated the predictive value of PD-L1 expression on ICI response. Conclusion: PD-L1 expression and association with ICI response varies across tissue sample sites. Specific molecular features are associated with differential expression of PD-L1 and may impact predictive capacity of PD-L1 for response to ICIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“The MSK-IMPACT assay was performed as previously described,[16, 17] for sequencing all exons and select introns of a custom gene panel of 341 (n = 13), 410 (n = 198), or 468 (n = 1375) genes.”
MethodSelf-citationMok, T. S. K., Wu, Y.-L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,303
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201
Self-citationMelanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 1×
“[36, 37] Meanwhile, pre-clinical and pre-clinical data support that STK11[11, 38–41] and WNT/β-catenin[15, 42, 43] signaling alterations are associated with an immunosuppressed tumor phenotype.”
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citationSTK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
Self-citationRizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367 · cited 1×
“Separately, although aneuploidy has been shown to correlate with decreased responses to immunotherapy in melanoma and lung cancer, it is not broadly associated with PD-L1 expression.[29, 32, 33]”
BackgroundSelf-citationDavoli, T., Uno, H., Wooten, E. C., & Elledge, S. J. (2017) · Science · doi:10.1126/science.aaf8399 · Cited by 1,360
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Shen, R., & Seshan, V. E. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw520 · Cited by 1,258
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science · doi:10.1126/science.aan5951 · Cited by 1,249
Self-citationGenomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Knijnenburg, T. A., Wang, L., Zimmermann, M. T., Chambwe, N., Gao, G. F., Cherniack, A. D., Fan, H., Shen, H., Way, G. P., Greene, C. S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.076 · Cited by 1,136
Self-citationSkoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936
Identification of essential genes for cancer immunotherapy
Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., Gartner, J. J., Jia, L., Steinberg, S. M., Yamamoto, T. N., et al. (2017) · Nature · doi:10.1038/nature23477 · Cited by 870
Roh, W., Chen, P.-L., Reuben, A., Spencer, C. N., Prieto, P. A., Miller, J. P., Gopalakrishnan, V., Wang, F., Cooper, Z. A., Reddy, S. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3560 · Cited by 859
Tsao, M. S., Kerr, K. M., Kockx, M., Beasley, M.-B., Borczuk, A. C., Botling, J., Bubendorf, L., Chirieac, L., Chen, G., Chou, T.-Y., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.013 · Cited by 794
Self-citationRimm, D. L., Han, G., Taube, J. M., Yi, E. S., Bridge, J. A., Flieder, D. B., Homer, R., West, W. W., Wu, H., Roden, A. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0013 · Cited by 764
WNT/β-catenin pathway activation correlates with immune exclusion across human cancers
Luke, J. J., Bao, R., Sweis, R. F., Spranger, S., & Gajewski, T. F. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1942 · Cited by 722
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G., & Bar-Sagi, D. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.024 · Cited by 721 · cited 1×
“[35] Similarly, RAS mutations induced changes in cytokine expression and immune-stimulatory transcription programs in multiple tumor models.[36, 37] Meanwhile, pre-clinical and pre-clinical data support that STK11[11, 38–41] and WNT/β-catenin[15, 42, 43] signaling alterations are associated with an immunosuppressed tu…”
BackgroundGenome doubling shapes the evolution and prognosis of advanced cancers
Bielski, C. M., Zehir, A., Penson, A. V., Donoghue, M. T. A., Chatila, W., Armenia, J., Chang, M. T., Schram, A. M., Jonsson, P., Bandlamudi, C., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0165-1 · Cited by 654
Self-citationKoyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1439 · Cited by 640
Self-citationCancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
Wellenstein, M. D., & de Visser, K. E. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.004 · Cited by 589
Ilie, M., Long-Mira, E., Bence, C., Butori, C., Lassalle, S., Bouhlel, L., Fazzalari, L., Zahaf, K., Lalvée, S., Washetine, K., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv489 · Cited by 587
Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma
Meylan, E., Dooley, A. L., Feldser, D. M., Shen, L., Turk, E., Ouyang, C., & Jacks, T. (2009) · Nature · doi:10.1038/nature08462 · Cited by 517
Arbour, K. C., Jordan, E., Kim, H. R., Dienstag, J., Yu, H. A., Sanchez-Vega, F., Lito, P., Berger, M., Solit, D. B., Hellmann, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1841 · Cited by 466
Self-citationHastings, K., Yu, H. A., Wei, W., Sanchez-Vega, F., DeVeaux, M., Choi, J., Rizvi, H., Lisberg, A., Truini, A., Lydon, C. A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz141 · Cited by 366
Self-citationMansfield, A. S., Aubry, M. C., Moser, J. C., Harrington, S. M., Dronca, R. S., Park, S. S., & Dong, H. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw289 · Cited by 336
Sabari, J. K., Leonardi, G. C., Shu, C. A., Umeton, R., Montecalvo, J., Ni, A., Chen, R., Dienstag, J., Mrad, C., Bergagnini, I., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy334 · Cited by 320
Self-citationK-ras activation generates an inflammatory response in lung tumors
Ji, H., Houghton, A. M., Mariani, T. J., Perera, S., Kim, C. B., Padera, R., Tonon, G., McNamara, K., Marconcini, L. A., Hezel, A., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209237 · Cited by 271
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
Adam, J., Le Stang, N., Rouquette, I., Cazes, A., Badoual, C., Pinot-Roussel, H., Tixier, L., Danel, C., Damiola, F., Damotte, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy014 · Cited by 215
A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
Gaule, P., Smithy, J. W., Toki, M., Rehman, J., Patell-Socha, F., Cougot, D., Collin, P., Morrill, P., Neumeister, V., & Rimm, D. L. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3015 · Cited by 201
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
Offin, M. D., Guo, R., Wu, S. L., Sabari, J. K., Land, J. D., Ni, A., Montecalvo, J., Halpenny, D. F., Buie, L. W., Pak, T., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00386 · Cited by 151
Self-citationA Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers
Sabari, J. K., Offin, M. D., Stephens, D. P., Ni, A., Lee, A. V., Pavlakis, N., Clarke, S. J., Diakos, C. I., Datta, S., Tandon, N., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy156 · Cited by 129
Self-citationSkoulidis, F., Arbour, K. C., Hellmann, M. D., Patil, P. D., Marmarelis, M. E., Awad, M. M., Murray, J. C., Hellyer, J., Gainor, J. F., Dimou, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.102 · Cited by 102 · cited 1×
“[15, 38, 44] Recently, it was additionally shown that patients with STK11 alterations who received platinum chemotherapy with immunotherapy may not benefit from the addition of immunotherapy.[39] Overall, the results of this report bolsters emerging mechanistic hypotheses related to these pathways and provides groundw…”
ResultSelf-citationComparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas
Kim, S., Koh, J., Kwon, D., Keam, B., Go, H., Kim, Y. A., Jeon, Y. K., & Chung, D. H. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.004 · Cited by 100
Pao, W. J., Ooi, C.-H., Birzele, F., Ruefli-Brasse, A. A., Cannarile, M. A., Reis, B., Scharf, S. H., Schubert, D. A., Hatje, K., Pelletier, N., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1320 · Cited by 99
Contraction of T cell richness in lung cancer brain metastases
Mansfield, A. S., Ren, H., Sutor, S. L., Sarangi, V., Nair, A., Davila, J. I., Elsbernd, L. R., Udell, J. B. M., Dronca, R. S., Park, S. S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20622-8 · Cited by 89
Velcheti, V., Patwardhan, P., Liu, F. X., Chen, X., Cao, X., & Burke, T. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206370 · Cited by 69
Boothman, A.-M., Scott, M. L. J., Ratcliffe, M., Whiteley, J. L., Dennis, P. A., Wadsworth, C., Sharpe, A. D., Rizvi, N. A., Garassino, M. C., & Walker, J. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.04.025 · Cited by 56
Humphries, M. P., McQuaid, S., Craig, S. G., Bingham, V., Maxwell, P., Maurya, M., McLean, F., Sampson, J., Higgins, P., Greene, C., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.025 · Cited by 53
Kerr, K. M., Thunnissen, E., Dafni, U. G., Finn, S. P., Bubendorf, L., Soltermann, A., Verbeken, E. K., Biernat, W., Warth, A., Marchetti, A., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.03.012 · Cited by 52
Shen, R., Martin, A. S., Ni, A., Hellmann, M. D., Arbour, K. C., Jordan, E., Arora, A., Ptashkin, R. N., Zehir, A., Kris, M. G., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00307 · Cited by 44
Self-citation
Cited by
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
CD8+ T cell differentiation and dysfunction in cancer
Philip, M., & Schietinger, A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00574-3 · Cited by 1,052
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Passaro, A., Al Bakir, M., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 672
Immune modulatory effects of oncogenic KRAS in cancer
Hamarsheh, S., Groß, O., Brummer, T., & Zeiser, R. (2020) · Nature Communications · doi:10.1038/s41467-020-19288-6 · Cited by 387
Schoenfeld, A. J., Bandlamudi, C., Lavery, J. A., Montecalvo, J., Namakydoust, A., Rizvi, H., Egger, J., Concepcion, C. P., Paul, S., Arcila, M. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1825 · Cited by 296
Self-citation
Metadata
- Authors
- Schoenfeld, A. J., Rizvi, H., Bandlamudi, C., Sauter, J. L., Travis, W. D., Rekhtman, N., Plodkowski, A. J., Perez-Johnston, R., Sawan, P., Beras, A., Egger, J. V., Ladanyi, M., Arbour, K. C., Rudin, C. M., Riely, G. J., Taylor, B. S., Donoghue, M. T. A., & Hellmann, M. D.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 31
- Issue
- 5
- Pages
- 599-608
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3005186000
- Cited by
- 324
- References
- 49
- FWCI
- 15.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.